Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells

Cancer Letters

Volumn 298, Issue 1, 2010, Pages 9-15

  Jung, Eun Uk ^a,b   Yoon, Jung Hwan ^a   Lee, Youn Jae ^b   Lee, Jeong Hoon ^a   Kim, Bo Hyun ^c   Yu, Su Jong ^a   Myung, Sun Jung ^a   Kim, Yoon Jun ^a   Lee, Hyo Suk ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Bundang Jesaeng Hospital   (South Korea)

Author keywords

Doxorubicin; Hepatocellular carcinoma; Hypoxia; N myc downstream regulated gene 1; Retinoic acid

Indexed keywords

CASPASE 9; DOXORUBICIN; FLAVOPIRIDOL; GLUTAREDOXIN; GLUTAREDOXIN 2; N MYC DOWNSTREAM REGULATED GENE 1 PROTEIN; REGULATOR PROTEIN; RETINOIC ACID; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; CELL CYCLE PROTEIN; N-MYC DOWNSTREAM-REGULATED GENE 1 PROTEIN; SIGNAL PEPTIDE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CARCINOMA, HEPATOCELLULAR; CELL HYPOXIA; DRUG RESISTANCE; GENETICS; LIVER NEOPLASMS; METABOLISM; MICROARRAY ANALYSIS; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL CYCLE PROTEINS; CELL HYPOXIA; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER NEOPLASMS; MICROARRAY ANALYSIS; TRETINOIN;

EID: 77956940122     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.05.020     Document Type: Article

References (30)

1. Mise M., Arii S., Higashituji H., Furutani M., Niwano M., Harada T., Ishigami S., Toda Y., Nakayama H., Fukumoto M., Fujita J., Imamura M. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996, 23:455-464.
2. Myung S.J., Yoon J.H., Kim K.M., Gwak G.Y., Kim Y.J., Yu J.W., Chung J.W., Lee H.S. Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments. Hepatogastroenterology 2006, 53:266-270.
3. Lopez R.R., Pan S.H., Hoffman A.L., Ramirez C., Rojter S.E., Ramos H., McMonigle M., Lois J. Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. Arch. Surg. 2002, 137:653-657. (discussion 657-658).
4. Tezuka M., Hayashi K., Kubota K., Sekine S., Okada Y., Ina H., Irie T. Growth rate of locally recurrent hepatocellular carcinoma after transcatheter arterial chemoembolization: comparing the growth rate of locally recurrent tumor with that of primary hepatocellular carcinoma. Dig. Dis. Sci. 2007, 52:783-788.
5. Gwak G.Y., Yoon J.H., Kim K.M., Lee H.S., Chung J.W., Gores G.J. Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J. Hepatol. 2005, 42:358-364.
6. Llovet J.M., Real M.I., Montana X., Planas R., Coll S., Aponte J., Ayuso C., Sala M., Muchart J., Sola R., Rodes J., Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359:1734-1739.
7. Lai C.L., Wu P.C., Chan G.C., Lok A.S., Lin H.J. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988, 62:479-483.
8. Zhou J., Schmid T., Schnitzer S., Brune B. Tumor hypoxia and cancer progression. Cancer Lett. 2006, 237:10-21.
9. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., Gu L.J., Wang Z.Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72:567-572.
10. Muto Y., Moriwaki H., Ninomiya M., Adachi S., Saito A., Takasaki K.T., Tanaka T., Tsurumi K., Okuno M., Tomita E., Nakamura T., Kojima T. Prevention of second primary tumors by an acyclic retinoid polyprenoic acid in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. New Engl. J. Med. 1996, 334:1561-1567.
11. Muto Y., Moriwaki H., Saito A. Prevention of second primary tumors by an acyclic retinoid in patients with hepatocellular carcinoma. New Engl. J. Med. 1999, 340:1046-1047.
12. You K.R., Shin M.N., Park R.K., Lee S.O., Kim D.G. Activation of caspase-8 during N-(4-hydroxyphenyl)retinamide-induced apoptosis in Fas-defective hepatoma cells. Hepatology 2001, 34:1119-1127.
13. Cangul H. Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet. 2004, 5:27.
14. Nakabayashi H., Taketa K., Miyano K., Yamane T., Sato J. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res. 1982, 42:3858-3863.
15. Park J.G., Lee J.H., Kang M.S., Park K.J., Jeon Y.M., Lee H.J., Kwon H.S., Park H.S., Yeo K.S., Lee K.U., et al. Characterization of cell lines established from human hepatocellular carcinoma. Int. J. Cancer 1995, 62:276-282.
16. Motwani M., Sirotnak F.M., She Y., Commes T., Schwartz G.K. Drg1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res. 2002, 62:3950-3955.
17. van Belzen N., Dinjens W.N., Diesveld M.P., Groen N.A., van der Made A.C., Nozawa Y., Vlietstra R., Trapman J., Bosman F.T. A novel gene which is up-regulated during colon epithelial cell differentiation and down-regulated in colorectal neoplasms. Lab. Invest. 1997, 77:85-92.
18. Piquemal D., Joulia D., Balaguer P., Basset A., Marti J., Commes T. Differential expression of the RTP/Drg1/Ndr1 gene product in proliferating and growth arrested cells. Biochim. Biophys. Acta 1999, 1450:364-373.
19. Xu B., Lin L., Rote N.S. Identification of a stress-induced protein during human trophoblast differentiation by differential display analysis. Biol. Reprod. 1999, 61:681-686.
20. Stein S., Thomas E.K., Herzog B., Westfall M.D., Rocheleau J.V., Jackson R.S., Wang M., Liang P. NDRG1 is necessary for p53-dependent apoptosis. J. Biol. Chem. 2004, 279:48930-48940.
21. Tu L.C., Yan X., Hood L., Lin B. Proteomics analysis of the interactome of N-myc downstream regulated gene 1 and its interactions with the androgen response program in prostate cancer cells. Mol. Cell. Proteomics 2007, 6:575-588.
22. Koshiji M., Kumamoto K., Morimura K., Utsumi Y., Aizawa M., Hoshino M., Ohki S., Takenoshita S., Costa M., Commes T., Piquemal D., Harris C.C., Tchou-Wong K.M. Correlation of N-myc downstream-regulated gene 1 expression with clinical outcomes of colorectal cancer patients of different race/ethnicity. World J. Gastroenterol. 2007, 13:2803-2810.
23. Angst E., Sibold S., Tiffon C., Weimann R., Gloor B., Candinas D., Stroka D. Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer. Br. J. Cancer 2006, 95:307-313.
24. Chua M.S., Sun H., Cheung S.T., Mason V., Higgins J., Ross D.T., Fan S.T., So S. Overexpression of NDRG1 is an indicator of poor prognosis in hepatocellular carcinoma. Mod. Pathol. 2007, 20:76-83.
25. Gladyshev V.N., Liu A., Novoselov S.V., Krysan K., Sun Q.A., Kryukov V.M., Kryukov G.V., Lou M.F. Identification and characterization of a new mammalian glutaredoxin (thioltransferase), Grx2. J. Biol. Chem. 2001, 276:30374-30380.
26. Lillig C.H., Lonn M.E., Enoksson M., Fernandes A.P., Holmgren A. Short interfering RNA-mediated silencing of glutaredoxin 2 increases the sensitivity of HeLa cells toward doxorubicin and phenylarsine oxide. Proc. Natl. Acad. Sci. USA 2004, 101:13227-13232.
27. Asmis R., Wang Y., Xu L., Kisgati M., Begley J.G., Mieyal J.J. A novel thiol oxidation-based mechanism for adriamycin-induced cell injury in human macrophages. FASEB J. 2005, 19:1866-1868.
28. Matsuzawa A., Ichijo H. Stress-responsive protein kinases in redox-regulated apoptosis signaling. Antioxid. Redox. Signal. 2005, 7:472-481.
29. Sedlacek H.H. Mechanisms of action of flavopiridol. Crit. Rev. Oncol. Hematol. 2001, 38:139-170.
30. Richard C., Matthews D., Duivenvoorden W., Yau J., Wright P.S., Th'ng J.P. Flavopiridol sensitivity of cancer cells isolated from ascites and pleural fluids. Clin. Cancer Res. 2005, 11:3523-3529.